Matches in DBpedia 2016-04 for { ?s ?p "Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. It is one of the most frequently used volume expanders under the trade names Hespan by B. Braun Medical Inc. Voluven or Volulyte by Fresenius Kabi and Tetrahes or Hestar by Claris Lifesciences Ltd.HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.Its use in those who are very ill is associated with an increased risk of death and kidney problems. The European Medicines Agency commenced in June 2013 the process of agreeing reduced indications which was completed in October 2013."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Hydroxyethyl_starch abstract "Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. It is one of the most frequently used volume expanders under the trade names Hespan by B. Braun Medical Inc. Voluven or Volulyte by Fresenius Kabi and Tetrahes or Hestar by Claris Lifesciences Ltd.HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.Its use in those who are very ill is associated with an increased risk of death and kidney problems. The European Medicines Agency commenced in June 2013 the process of agreeing reduced indications which was completed in October 2013.".
- Q415775 abstract "Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. It is one of the most frequently used volume expanders under the trade names Hespan by B. Braun Medical Inc. Voluven or Volulyte by Fresenius Kabi and Tetrahes or Hestar by Claris Lifesciences Ltd.HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.Its use in those who are very ill is associated with an increased risk of death and kidney problems. The European Medicines Agency commenced in June 2013 the process of agreeing reduced indications which was completed in October 2013.".